Did GRAIL CEO step down?
GRAIL has made significant progress in its pursuit of regulatory validation for its Galleri test, a multicancer early detection (MCED) test. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), which is designed to expedite the development and review of medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human conditions. While this designation is a major milestone, it is not synonymous with full commercial approval. The company continues to work closely with the FDA to conduct the rigorous clinical trials and provide the analytical data necessary for full premarket approval, ensuring that its technology meets the stringent standards required for broad clinical adoption and reimbursement across the United States.
Related FAQs
Investors can purchase shares in Hanwha Corporation and its various publicly traded subsidiaries—such as Hanwha Solutions, Hanwha Aerospace, and Hanwha Ocean—by utilizing brokerage accounts that provide access to the Korea Exchange where these ent...
Yes, Granite Construction Incorporated completed the acquisition of the construction business of Papich Construction Company, Inc. in late 2024.
Grange Insurance maintains strong financial strength and credit ratings, typically holding an "A" (Excellent) or higher rating from prominent independent insurance rating organizations such as AM Best.
Grange Insurance has been operating as a trusted property and casualty insurance provider for over nine decades, having been officially founded in December 1935.
Graphic Packaging Holding Company commands a corporate market capitalization of approximately $3.21 billion to $3.31 billion USD.
The Galleri multi-cancer early detection blood test is an innovative liquid biopsy designed to screen for dozens of different types of cancer through a single blood draw.
Traditional federal Medicare does not currently cover the cost of the Galleri multi-cancer early detection blood test, meaning patients typically must pay out of pocket.